{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"395"},{"groupId":"OG001","value":"236"}]}],"title":"ISS Stage I"},{"categories":[{"measurements":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"267"}]}],"title":"ISS Stage II"},{"categories":[{"measurements":[{"groupId":"OG000","value":"520"},{"groupId":"OG001","value":"297"}]}],"title":"ISS Stage III"},{"categories":[{"measurements":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"376"}]}],"title":"ISS Not Available"},{"categories":[{"measurements":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"264"}]}],"title":"ISS Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"40"}]}],"title":"R-ISS Stage I"},{"categories":[{"measurements":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"145"}]}],"title":"R-ISS Stage II"},{"categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"24"}]}],"title":"R-ISS Stage III"},{"categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"285"}]}],"title":"R-ISS Not available"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1170"},{"groupId":"OG001","value":"946"}]}],"title":"R-ISS Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1761"},{"groupId":"OG001","value":"1440"}],"units":"Participants"}],"description":"ISS disease stages were defined as I:low risk, β2-Microglobulin\\<3.5mg/L, albumin≥3.5g/dL, II:not stage I or III, III:high risk,β2-Microglobulin≥5.5mg/L). R-ISS is based on ISS, chromosomal abnormalities (CA), and lactate dehydrogenase (LDH). R-ISS disease stages were defined as I: ISS Stage I and standard risk CA by FISH and normal LDH (i.e. \\<=300 U/L), II: Neither R-ISS Stage I nor Stage III, III: ISS Stage III and either high risk CA by FISH or high LDH (i.e. \\>300 U/L).","groups":[{"description":"Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).","id":"OG000","title":"NDMM"},{"description":"Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).","id":"OG001","title":"RRMM"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Enrolled Population included all participants who signed informed consent. Overall number of participants are the number of participants available for analysis.","reportingStatus":"POSTED","timeFrame":"At Baseline","title":"Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage","type":"PRIMARY","unitOfMeasure":"Participants"}